Recap: Aura Biosciences Q4 Earnings

3/27/24 9:25:06 AM ET

$AURA

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $AURA alert in real time by email

Aura Biosciences (NASDAQ:AURA) reported its Q4 earnings results on Wednesday, March 27, 2024 at 07:00 AM.

Here's what investors need to know about the announcement.

Earnings

Aura Biosciences beat estimated earnings by 73.0%, reporting an EPS of $-0.5 versus an estimate of $-1.82.

Revenue was down $0 from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.04 which was followed by a 10.0% increase in the share price the next day.

** Listen to the earnings announcement yourself by clicking here. **

To track all earnings releases for Aura Biosciences visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Get the next $AURA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AURA

Date	Price Target	Rating	Analyst
7/25/2024	$21.00	Buy	H.C. Wainwright
7/27/2023		Sector Outperform	Scotiabank
4/17/2023	$38.00	Buy	BTIG Research
7/19/2022	$26.00	Mkt Outperform	JMP Securities
11/24/2021	$40.00	Outperform	SVB Leerink
11/23/2021	$38.00	Buy	BTIG Research
11/23/2021		Outperform	Cowen
11/23/2021	$35.00	Outperform	Evercore ISI

More analyst ratings

$AURA
Press Releases

Fastest customizable press release news feed in the world

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple Clinical Complete Responses Observed with Single Low Dose of Bel-sar in Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC); Phase 1 Expansion Preparation in Progress Strong Cash Position Expected to Support Operations into 2H 2026 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the thir
11/12/24 4:05:00 PM ET
$AURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Aura Hosting Virtual Urologic Oncology Investor Event with Key Opinion Leaders at 4.30 pm ET Today BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), today announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with NMIBC. To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility of
10/17/24 4:05:00 PM ET
$AURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders Today at 8:00 am ET BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced positive Phase 2 end of study results evaluating bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a vision and life-threatening ocular cancer. The results were presented at The Retina Society Annual Meeting, on Thursday
9/12/24 6:30:00 AM ET
$AURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Recap: Aura Biosciences Q4 Earnings

Earnings

Past Earnings Performance

Chat with this insight

Recent Analyst Ratings for $AURA

$AURA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

$AURA Leadership Updates

Live Leadership Updates

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

$AURA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$AURA SEC Filings

Johnson David Michael bought $1,434,987 worth of shares (199,601 units at $7.19), increasing direct ownership by 171% to 135,667 units (SEC Form 4)

Matrix Capital Management Company, Lp bought $14,040,000 worth of shares (1,560,000 units at $9.00) (SEC Form 4)

Johnson David Michael bought $168,175 worth of shares (20,066 units at $8.38), increasing direct ownership by 67% to 50,066 units (SEC Form 4)

SEC Form 10-Q filed by Aura Biosciences Inc.

Aura Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

Aura Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

$AURA Market Insights

Live Market Insights

HC Wainwright & Co. Initiates Coverage On Aura Biosciences with Buy Rating, Announces Price Target of $21